DUBLIN--(BUSINESS WIRE)--The "Global Companion Diagnostics Market Analysis 2019" report has been added to ResearchAndMarkets.com's offering.
The Global Companion Diagnostics market is expected to reach $11.12 billion by 2026 growing at a CAGR of 17.7% from 2018 to 2026.
A companion diagnostic is an in vitro medicinal device that provides data which is fundamental for the safe and effective utilization of a corresponding drug or biological product. This diagnostic test helps a health care professional to decide if a particular therapeutic product is beneficial to patients and can outweigh any potentially serious side effects or risks.
Some of the factors such as increasing importance of personalized medicine and rising global incidence of cancer are fuelling the market growth. However, uncertain reimbursement scenario in different regions is restraining the market growth.
Based on the technology, immunohistochemistry (IHC) segment has witnessed significant growth. Immunohistochemistry involves identification of antigens through antigen-antibody binding principle. This technology further allows evaluation of drug contingency with significant accuracy. Successful outcomes acquired with the use of immunohistochemistry technology will enlarge its preference, thereby propelling immunochemistry technology segment growth.
The key vendors mentioned are Thermo Fisher Scientific, Inc., Sysmex Corporation, QIAGEN N.V., Myriad Genetics, Inc., Illumina Inc., Guardant Health, Inc., F. Hoffmann-La Roche AG, Danaher Corporation, bioMrieux SA, Almac Group, Agilent Technologies, Inc.,
Abnova Corporation, and Abbott Laboratories, Inc.
Key Questions Answered in this Report:
- How this market evolved since the year 2016
- Market size estimations, forecasts and CAGR for all the segments presented in the scope
- Key Market Developments and financials of the key players
- Opportunity Analysis for the new entrants
- SWOT Analysis of the key players
Fastest growing markets analyzed during the forecast period
Key Topics Covered:
1 Market Synopsis
2 Research Outline
3 Market Dynamics
4 Market Environment
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Companion Diagnostics Market, By Product & Service
5.2 Software & Services
5.3 Assays, Kits, & Reagents
6 Global Companion Diagnostics Market, By Technology
6.2 Polymerase Chain Reaction (PCR)
6.3 Molecular Diagnostics
6.4 Immunohistochemistry (IHC)
6.5 Next-Generation Sequencing (NGS)
6.6 In Situ Hybridization (ISH)
6.7 Gene Sequencing
6.8 Other Technologies
7 Global Companion Diagnostics Market, By Indication
7.3 Neurological Diseases
7.4 Inflammation and Autoimmune Diseases
7.5 Infectious Diseases
7.6 Cardiovascular Diseases
7.8 Other Indications
8 Global Companion Diagnostics Market, By End User
8.2 Reference Laboratories
8.3 Pharmaceutical & Biopharmaceutical Companies
8.4 Independent Clinical Laboratories
8.5 Contract Research Organizations
8.6 Other End Users
9 Global Companion Diagnostics Market, By Geography
9.2 North America
9.4 Asia Pacific
9.5 South America
9.6 Middle East & Africa
10 Strategic Benchmarking
11 Vendors Landscape
11.1 Thermo Fisher Scientific, Inc.
11.2 Sysmex Corporation
11.3 QIAGEN N.V.
11.4 Myriad Genetics, Inc.
11.5 Illumina Inc.
11.6 Guardant Health, Inc.
11.7 F. Hoffmann-La Roche AG
11.8 Danaher Corporation
11.9 bioMrieux SA
11.10 Almac Group
11.11 Agilent Technologies, Inc.
11.12 Abnova Corporation
11.13 Abbott Laboratories, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/q9r4ah